

Product datasheet for **TL317115V**

TOR2A Human shRNA Lentiviral Particle (Locus ID 27433)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	TOR2A Human shRNA Lentiviral Particle (Locus ID 27433)
Locus ID:	27433
Synonyms:	TORP1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	TOR2A - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001085347 , NM_001134430 , NM_001134431 , NM_001252018 , NM_001252021 , NM_001252023 , NM_130459 , NM_130459.1 , NM_130459.2 , NM_130459.3 , NM_001085347.1 , NM_001085347.2 , NM_001134431.1 , NM_001134431.2 , NM_001134430.1 , NM_001134430.2 , NM_001252023.1 , NM_001252018.1 , NM_001252021.1 , BC022985 , BC062340 , BC080527 , BC100907 , BC100908 , BC100909 , BC100910 , BC156122 , BC156918 , BC160144 , BM695589 , BM772287 , NM_001252023.2 , NM_130459.4 , NM_001134430.3 , NM_001134431.3 , NM_001085347.3
UniProt ID:	Q5JU69
Summary:	This gene encodes a member of the AAA family of adenosine triphosphatases with similarity to Clp proteases and heat shock proteins. Alternative splicing at this locus results in the translation of multiple isoforms of the encoded protein, some of which contain salusin peptides in the C-terminal region. These peptides may play roles in hypotension, myocardial growth and the induction of mitogenesis, and may also be involved in the pathogenesis of atherosclerosis. The antimicrobial peptide salusin-beta has antibacterial activity. [provided by RefSeq, Nov 2014]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).